CN116999519A - 一种治疗高血脂症的药菌组合物及其制备方法和应用 - Google Patents
一种治疗高血脂症的药菌组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN116999519A CN116999519A CN202311030575.3A CN202311030575A CN116999519A CN 116999519 A CN116999519 A CN 116999519A CN 202311030575 A CN202311030575 A CN 202311030575A CN 116999519 A CN116999519 A CN 116999519A
- Authority
- CN
- China
- Prior art keywords
- vinegar
- mixture
- hyperlipidemia
- tea
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 241000233866 Fungi Species 0.000 title claims abstract description 41
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 235000021419 vinegar Nutrition 0.000 claims abstract description 81
- 239000000052 vinegar Substances 0.000 claims abstract description 81
- 241000702462 Akkermansia muciniphila Species 0.000 claims abstract description 41
- 239000000843 powder Substances 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 8
- 244000269722 Thea sinensis Species 0.000 claims description 64
- 235000013616 tea Nutrition 0.000 claims description 53
- 238000002156 mixing Methods 0.000 claims description 33
- 235000013399 edible fruits Nutrition 0.000 claims description 32
- 241000894006 Bacteria Species 0.000 claims description 19
- 230000001954 sterilising effect Effects 0.000 claims description 19
- 238000010298 pulverizing process Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 13
- 244000157072 Hylocereus undatus Species 0.000 claims description 12
- 235000018481 Hylocereus undatus Nutrition 0.000 claims description 12
- 235000009569 green tea Nutrition 0.000 claims description 11
- 244000298697 Actinidia deliciosa Species 0.000 claims description 10
- 235000009436 Actinidia deliciosa Nutrition 0.000 claims description 10
- 235000003953 Solanum lycopersicum var cerasiforme Nutrition 0.000 claims description 10
- 240000003040 Solanum lycopersicum var. cerasiforme Species 0.000 claims description 10
- 229940041514 candida albicans extract Drugs 0.000 claims description 10
- 239000012138 yeast extract Substances 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 7
- 238000000855 fermentation Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 241000220225 Malus Species 0.000 claims 1
- 235000011430 Malus pumila Nutrition 0.000 claims 1
- 235000015103 Malus silvestris Nutrition 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 14
- 210000004369 blood Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 11
- 150000002632 lipids Chemical class 0.000 abstract description 8
- 239000006041 probiotic Substances 0.000 abstract description 7
- 235000018291 probiotics Nutrition 0.000 abstract description 7
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 6
- 229930003944 flavone Natural products 0.000 abstract description 6
- 150000002212 flavone derivatives Chemical class 0.000 abstract description 6
- 235000011949 flavones Nutrition 0.000 abstract description 6
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 6
- 230000000968 intestinal effect Effects 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 3
- 150000007524 organic acids Chemical class 0.000 abstract description 3
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 230000001603 reducing effect Effects 0.000 abstract description 2
- 241001122767 Theaceae Species 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 108010059892 Cellulase Proteins 0.000 description 8
- 229940106157 cellulase Drugs 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000000227 grinding Methods 0.000 description 7
- 238000004537 pulping Methods 0.000 description 7
- 239000000084 colloidal system Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 235000021022 fresh fruits Nutrition 0.000 description 6
- 238000011059 hazard and critical control points analysis Methods 0.000 description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 description 6
- 235000013824 polyphenols Nutrition 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 102000000591 Tight Junction Proteins Human genes 0.000 description 2
- 108010002321 Tight Junction Proteins Proteins 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- 230000004609 intestinal homeostasis Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 241000702460 Akkermansia Species 0.000 description 1
- 241000778935 Akkermansia muciniphila ATCC BAA-835 Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- -1 flavonoid compounds Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000021070 high sugar diet Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
- A23L33/145—Extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗高血脂症的药菌组合物及其制备方法和应用,属于生物技术领域。本发明为克服传统药物治疗高血脂症时对肝肾带来的负担,以及对机体造成的副作用,在具有降血脂作用的醋膏茶粉混合物中加入了肠道益生菌Akkermansia muciniphila,这使得比传统药物治疗途径更多样,对高血脂症的治疗效果更佳。除此之外,提供了一种治疗高血脂症的药菌组合物的制备方法,可以有效提中药材的有效利用率,且药菌组合物中含有益生菌、有机酸、黄酮、氨基酸等功能成分,对高血脂症的治疗效果显著,同时节约原料成本。
Description
技术领域
本发明涉及一种治疗高血脂症的药菌组合物及其制备方法和应用,属于生物技术领域。
背景技术
高脂血症是一种包含各种遗传和获得性疾病的疾病,这种疾病人体内脂质水平升高。据统计,中国成年人血脂异常的发病率超过了25%,即每4个人中就有一位潜在的高脂血症患者。据世界卫生组织统计,每年大约有1700万人死于这种慢性疾病,占全球总死亡人数的30%左右。影响人体血脂水平的主要因素为环境因素,包括高胆固醇、高糖饮食以及肥胖久坐等原因。
目前,对于高脂血症的治疗大多为西药治疗,当体内血脂达到一定指标才能服用降血脂药,如:他汀类、贝特类以及烟酸类等,而药物治疗对人体的副作用大,而且长期的服药会给肝,肾器官增加一定的负担;同时如果症状较轻可以通过饮食运动控制,但是需要长期坚持才能达到一定的效果。菌类药物由于低毒、安全、具有调节免疫功能等药理活性,被认为是新的药物发展趋势。
Akkermansia muciniphila是2004年Derrien在人类粪便中发现的一种新的粘蛋白降解菌,属于疣菌门。Akkermansia muciniphila在人类肠道中普遍存在,以粘蛋白为食,肠道中低浓度的Akkermansia muciniphila可能表明黏液层较薄,从而导致肠道屏障功能减弱。Akkermansia muciniphila以及其分泌物与结肠上皮细胞Toll受体结合及调节紧密连接蛋白的表达等来维持肠道稳态,从而改善高脂饮食诱导的肥胖和炎症性肠病等疾病。现有报道中指出,通过调节肠道微生物菌落中Akkermansia muciniphila等有益菌的丰度,可抑制血糖或血脂的水平,但治疗效果非常有限。
发明内容
为解决上述问题,本发明结合了中药和益生菌,在醋膏中加入了茶粉和肠道益生菌Akkermansia muciniphila进行发酵,可以作为治疗高血脂症的药物,对人体的代谢负担较小并且起效时间较饮食运动控制较短,克服了传统药物治疗可能对机体造成的不良反应,也具有重要的社会前景和经济效益。
本发明的第一个目的是提供一种治疗高血脂症的药菌组合物的制备方法,包括以下步骤:
S1、通过蒸馏浓缩方法制备醋膏,与茶粉混合,获得茶醋混合物;
S2、将嗜黏蛋白阿克曼氏菌(Akkermansia muciniphila)在35~38℃下厌氧发酵35~45h,得到活菌;
S3、将上述茶醋混合物加入活菌培养基中,在35~38℃下厌氧发酵15~35h,得到药菌混合物;
S4、对上述药菌混合物进行调配,灭菌后得到所述治疗高血脂症的药菌组合物。
高血脂症与进食含脂肪和胆固醇类食物过多,同时与遗传因素等有关系。高血脂对身体的损害是隐匿、逐渐、进行性和全身性的,它的直接损害是加速全身动脉粥样硬化,因为全身的重要器官都要依靠动脉供血、供氧,一旦动脉被粥样斑块堵塞,就会导致严重后果。
本发明中的绿茶叶富含生物碱、脂肪、游离氨基酸、有机酸、蛋白质、糖类以及茶多酚组成。其中,茶多酚含量占较大比重,而茶多酚是由儿茶素、黄酮、花青素等物质组成,黄酮类在抗氧化,抑制脂肪酶,抗癌,抗菌消炎等方面有重要作用。
本发明利用超微粉碎法对绿茶叶进行粉碎,对绿茶叶破壁率高,所得的茶叶颗粒细腻,复水性更好,有利于药物的释放和吸收,药效能明显得到增强。
本发明中的醋膏是传统药食同源中药材,富含有机酸、多糖、蛋白、黄酮、多酚、川芎嗪等活性物质,有通过饮食干预,有效降低体内胆固醇、甘油三酯、低密度脂蛋白胆固醇含量,提高体内高密度脂蛋白胆固醇含量,降低肝脏中丙二醛含量,具有一定降血脂作用;并且多酚和黄酮类化合物具有抗氧化作用,能够抑制脂质过氧化以及脂肪酶活性。不仅如此,醋膏也能通过增加肠道潜在有益菌Akkermansia等来影响肠道及机体健康。
除此之外,本发明利用蒸馏浓缩技术制备醋膏,提升醋膏的陈化速率,加速活性成分富集,提高醋膏功能及品质。
本发明中茶醋混合物联合了活的Akkermansia muciniphila菌。Akkermansiamuciniphila以及其分泌物与结肠上皮细胞Toll受体结合及调节紧密连接蛋白的表达等来维持肠道稳态,从而改善高脂饮食诱导的肥胖和炎症性肠病等疾病。此外,茶醋混合物联合Akkermansia muciniphila菌可调节肠道菌群,增强肠道屏障功能,进一步减少LPS的产生,对治疗高血脂症起到一定作用。
进一步地,在步骤S1中,所述醋膏的制备方法为,将食醋于60℃~80℃加热蒸馏浓缩20~30h,收集浓缩醋液,向其中加入酵母抽提物,混匀后分层,取下层液得到醋膏。
进一步地,浓缩醋液与酵母抽提物的质量比为100-300:1-1.5。
进一步地,所述茶粉通过超微粉碎法将绿茶叶粉碎得到。具体地,利用超微粉碎法将优质的绿茶叶进行粉碎,粉碎时超微粉碎机转速为340-360r/min,球料比为7-9,粉碎时间3-4h,获得茶粉。
进一步地,茶醋混合物中,醋膏为茶粉质量的20~30%。
进一步地,在步骤S1中还包括对醋膏进行过滤除杂、均质、灭菌处理的步骤。
进一步地,均质包括但不限于高压均质使醋膏颗粒均一,如在20℃~30℃、压力15~25MPa条件下经均质机处理。
进一步地,灭菌包括但不限于高温灭菌,如在130-170℃下进行灭菌。
进一步地,在步骤S2或S3中,根据HACCP质量体系,使用食品级培养基对嗜黏蛋白阿克曼氏菌(Akkermansia muciniphila)进行培养。
进一步地,所述嗜黏蛋白阿克曼氏菌(Akkermansia muciniphila)为Akkermansiamuciniphila ATCC BAA-835,购自美国模式菌种收集中心(ATCC)。
进一步地,在步骤S3中,所述嗜黏蛋白阿克曼氏菌(Akkermansia muciniphila)的添加量为4×108~4×1011个/100mL茶醋混合物。
进一步地,在步骤S4中,所述的调配为,向所述药菌混合物中加入果浆。本发明中果浆是火龙果,猕猴桃和圣女果的混合果浆。火龙果含有益生元,可以喂养肠道中称为益生菌的健康细菌;并且火龙果能降低血糖促进消化吸收。此果浆富含果胶、黄酮、多酚、维生素等,其具有增强和调节人体免疫力,抗氧化,抗炎等功能。同时,水果果浆也可以改善药菌组合物的口感。
进一步地,果浆添加量为调配后的药菌混合物质量的10%~20%。
进一步地,所述果浆为水果果肉打浆、酶解得到的澄清果浆。
进一步地,所述酶解过程为,分别向经打浆的果肉中加入纤维素酶和果胶酶进行酶解,酶解温度为45~55℃,酶解时间2~3h。
进一步地,添加果肉总质量0.1%~0.2%的纤维素酶和0.2%~0.3%果胶酶进行酶解。
进一步地,所述水果选自苹果、火龙果、圣女果和猕猴桃中的至少两种,优选地,果肉原料为火龙果、猕猴桃和圣女果按照质量比7~8:6~7:4~5混合。
进一步地,在步骤S4中,以140~160MPa,40~50℃对调配后的药菌混合物进行高压均质杀菌。
本发明的第二个目的是提供上述制备方法得到的药菌组合物。
本发明的第三个目的是提供上述药菌组合物在制备高血脂症预防或治疗药物中的应用。
本发明的有益效果:
(1)本发明在临床检测数据分析基础上,通过大量的动物实验筛选,深入研究,提供药菌组合物在治疗高血脂症的新用途。实验结果表明,给大鼠灌胃药菌组合物后可显著降血脂水平,对高血脂症模型大鼠起到治疗的作用。此外,实验结果表明本发明的药菌组合物的疗效可靠,使用安全,无毒副作用,可以用于制备治疗高血脂症的食品或者药物。
(2)本发明在茶醋混合物中加入了肠道益生菌Akkermansia muciniphila进行发酵,相比传统复配的药菌组合物,有效提高了药材的利用率,克服了传统药物治疗对机体造成的不良反应,且经验证,本发明的益生菌发酵得到的药菌组合物还提高了高血脂症的治疗效果。
具体实施方式
下面结合具体实施例对本发明作进一步说明,以使本领域的技术人员可以更好地理解本发明并能予以实施,但所举实施例不作为对本发明的限定。
下述实施例中涉及的材料及方法如下:
酵母抽提物:安琪酵母。
Akkermansia muciniphila菌:Cat.No.BAA-835,购自美国模式菌种收集中心(ATCC)。
Akkermansia muciniphila菌培养基:标准脑心浸液液体培养基(BHI)基础成分中添加以下成分:黏蛋白(0.25%),L-半胱氨酸(每10mL培养基加入0.1mL 3%的储备液)。
实施例1:治疗高血脂症的药菌组合物的制备方法
(1)茶醋混合物的制备:利用超微粉碎法将优质的绿茶叶进行粉碎,粉碎时超微粉碎机转速为340r/min,球料比为8,粉碎时间3h,获得茶粉。将食醋进行加热浓缩,加热温度为80℃,时间为20h,收集蒸馏醋液和浓缩醋液。向浓缩醋液中以1:200比例加入一定量的酵母抽提物,混匀静置取下层液得到调配醋膏。再加入茶粉质量的20%的醋膏进行混合,获得茶醋混合物;
(2)制备Akkermansia muciniphila菌:根据HACCP质量体系,使用食品级培养基对细菌进行培养,在37℃的厌氧条件下发酵40h,获得活的Akkermansia muciniphila菌备用;
(3)水果原料预处理:将水果原料进行两次清洗或取果肉,火龙果,猕猴桃和圣女果按照质量比7:6:4混合进行打浆,向经打浆的果肉中添加果肉总质量0.1%的纤维素酶和0.2%果胶酶,酶解温度为45-55℃,酶解时间2-3h。胶体磨磨浆后,得到新鲜果浆备用;
(4)药菌混合物的制备:将所述步骤(1)得到的茶醋混合物中加入步骤(2)所得活的Akkermansia muciniphila菌,在37℃的厌氧条件下发酵15h,获得药菌混合物;
其中活的Akkermansia muciniphila菌的添加量为4×108个/100mL茶醋混合物
(5)调配:向所述步骤(4)所得药菌混合物中加入步骤(3)所得果浆进行调配;
其中澄清果浆为药菌混合物质量的10%。
(6)高压均质灭菌:以150MPa,45℃对药菌组合物进行均质杀菌处理,最终得到治疗高血脂症的药菌组合物。
实施例2:治疗高血脂症的药菌组合物的制备方法
(1)茶醋混合物的制备:利用超微粉碎法将优质的绿茶叶进行粉碎,粉碎时超微粉碎机转速为350r/min,球料比为7,粉碎时间3.5h,获得茶粉。将食醋进行加热浓缩,加热温度为80℃,时间为20h,收集蒸馏醋液和浓缩醋液。向浓缩醋液中以1:200比例加入一定量的酵母抽提物,混匀静置取下层液得到调配醋膏。再加入茶粉质量的30%的醋膏进行混合,获得茶醋混合物。
(2)制备Akkermansia muciniphila菌:根据HACCP质量体系,使用食品级培养基对细菌进行培养,在37℃的厌氧条件下发酵42h,获得活的Akkermansia muciniphila菌备用;
(3)水果原料预处理:将水果原料进行两次清洗或取果肉,火龙果,猕猴桃和圣女果按照质量比8:7:4混合进行打浆,向经打浆的果肉中添加果肉总质量0.1%的纤维素酶和0.2%果胶酶,酶解温度为45-55℃,酶解时间2-3h。胶体磨磨浆后,得到新鲜果浆备用;
(4)药菌混合物的制备:将所述步骤(1)得到的茶醋混合物中加入步骤(2)所得活的Akkermansia muciniphila菌,在37℃的厌氧条件下发酵20h,获得药菌混合物;
其中活的Akkermansia muciniphila菌的添加量为4×108个/100mL茶醋混合物。
(5)调配:向所述步骤(4)所得药菌混合物中加入步骤(3)所得果浆进行调配;
其中果浆添加量为药菌混合物质量的15%。
(6)高压均质灭菌:以150MPa,45℃对药菌组合物进行均质杀菌处理,最终得到治疗高血脂症的药菌组合物。
实施例3:治疗高血脂症的药菌组合物的制备方法
(1)茶醋混合物的制备:利用超微粉碎法将优质的绿茶叶进行粉碎,粉碎时超微粉碎机转速为350r/min,球料比为8,粉碎时间3.5h,获得茶粉。将食醋进行加热浓缩,加热温度为80℃,时间为20h,收集蒸馏醋液和浓缩醋液。向浓缩醋液中以1:200比例加入一定量的酵母抽提物,混匀静置取下层液得到调配醋膏。再加入茶粉质量的20%的醋膏进行混合,获得茶醋混合物。
(2)制备Akkermansia muciniphila菌:根据HACCP质量体系,使用食品级培养基对细菌进行培养,在37℃的厌氧条件下发酵40h,获得活的Akkermansia muciniphila菌备用;
(3)水果原料预处理:将水果原料进行两次清洗或取果肉,火龙果,猕猴桃和圣女果按照质量比8:7:5混合进行打浆,向经打浆的果肉中添加果肉总质量0.1%的纤维素酶和0.2%果胶酶,酶解温度为45-55℃,酶解时间2-3h。胶体磨磨浆后,得到新鲜果浆备用;
(4)药菌混合物的制备:将所述步骤(1)得到的茶醋混合物中加入步骤(2)所得活的Akkermansia muciniphila菌,在37℃的厌氧条件下发酵15h,获得药菌混合物;
其中活的Akkermansia Muciniphila菌的添加量为4×109个/100mL茶醋混合物。
(5)调配:向所述步骤(4)所得药菌混合物中加入步骤(3)所得果浆进行调配;
其中果浆添加量为药菌混合物质量的10%。
(6)高压均质灭菌:以150MPa,45℃对药菌组合物进行均质杀菌处理,最终得到治疗高血脂症的药菌组合物。
对比例1
(1)茶醋混合物的制备:利用超微粉碎法将优质的绿茶叶进行粉碎,粉碎时超微粉碎机转速为350r/min,球料比为8,粉碎时间3.5h,获得茶粉。将食醋进行加热浓缩,加热温度为80℃,时间为20h,收集蒸馏醋液和浓缩醋液。向浓缩醋液中以1:200比例加入一定量的酵母抽提物,混匀静置取下层液得到调配醋膏。再加入茶粉质量的20%的醋膏进行混合,获得茶醋混合物。
(2)水果原料预处理:将水果原料进行两次清洗或取果肉,火龙果,猕猴桃和圣女果按照质量比8:7:5混合进行打浆,向经打浆的果肉中添加果肉总质量0.1%的纤维素酶和0.2%果胶酶,酶解温度为45-55℃,酶解时间2-3h。胶体磨磨浆后,得到新鲜果浆备用;
(3)调配:向所述步骤(1)所得茶醋混合物中加入步骤(2)所得果浆进行调配;
其中果浆添加量为茶醋混合物质量的10%。
(6)高压均质灭菌:以150MPa,45℃对药物组合物进行均质杀菌处理。
对比例2
(1)制备Akkermansia muciniphila菌:根据HACCP质量体系,使用食品级培养基对细菌进行培养,在37℃的厌氧条件下发酵40h,获得活的Akkermansia muciniphila菌备用;
(2)水果原料预处理:将水果原料进行两次清洗或取果肉,火龙果,猕猴桃和圣女果按照质量比8:7:5混合进行打浆,向经打浆的果肉中添加果肉总质量0.1%的纤维素酶和0.2%果胶酶,酶解温度为45-55℃,酶解时间2-3h。胶体磨磨浆后,得到新鲜果浆备用;
(3)调配:将所述步骤(1)得到的活的Akkermansia muciniphila菌中加入步骤(2)所得的水果果浆,获得复配混合物;
其中4×109灭活的Akkermansia muciniphila菌中添加100mL水果果浆。
(4)高压均质灭菌:以150MPa,45℃对药物组合物进行均质杀菌处理。
对比例3
(1)茶醋混合物的制备:利用超微粉碎法将优质的绿茶叶进行粉碎,粉碎时超微粉碎机转速为350r/min,球料比为8,粉碎时间3.5h,获得茶粉。将食醋进行加热浓缩,加热温度为80℃,时间为20h,收集蒸馏醋液和浓缩醋液。向浓缩醋液中以1:200比例加入一定量的酵母抽提物,混匀静置取下层液得到调配醋膏。再加入茶粉质量的20%的醋膏进行混合,获得茶醋混合物。
(2)制备Akkermansia muciniphila菌:根据HACCP质量体系,使用食品级培养基对细菌进行培养,在37℃的厌氧条件下发酵40h,获得活的Akkermansia muciniphila菌备用;
(3)水果原料预处理:将水果原料进行两次清洗或取果肉,火龙果,猕猴桃和圣女果按照质量比8:7:5混合进行打浆,向经打浆的果肉中添加果肉总质量0.1%的纤维素酶和0.2%果胶酶,酶解温度为45-55℃,酶解时间2-3h。胶体磨磨浆后,得到新鲜果浆备用;
(4)复配:将所述步骤(1)得到的茶醋混合物中加入步骤(2)所得活的Akkermansiamuciniphila菌,获得复配混合物;
其中活的Akkermansia muciniphila菌的添加量为4×109个/100mL茶醋混合物。
(5)调配:向所述步骤(4)所得复配混合物中加入步骤(3)所得果浆进行调配;
其中果浆添加量为复配混合物质量的10%。
(6)高压均质灭菌:以150MPa,45℃对复配组合物进行均质杀菌处理。
测试例治疗高血脂症的药菌组合物的应用性能
(1)实验动物:
SD大鼠,5~6周雄性,90只。
实验试剂:
实施例1、实施例2、实施例3、对比例1、对比例2、对比例3的组合物、高脂饲料(78%配方基础饲料、1%胆固醇、10%蛋黄粉和10%猪油、1%胆盐)、洛伐他汀片
实验方法:
将大鼠随机分成9组,每组10只,分为正常组、模型组、给药组1、给药组2、给药组3、给药组4、给药组5、给药组6和阳性对照组。分组及给药关系如表1所示。
表1分组及给药情况
大鼠经过一周适应性培养,正常组正常饮食饮水;模型组进行高脂饲料饮食20天;实验组进行高脂饲料饮食10天,第10天至第20天每天灌胃组合物或洛伐他汀片,剂量分别为4mL/kg和0.15g/kg。第21天,断颈法处死。收集大鼠的血清,检测大鼠血清中TG、TC、HDL-C。
表2各组大鼠血清中相关指标的统计结果
注:###与正常组相比较,P<0.001;##与正常组相比较,P<0.01;#与正常组相比较,P<0.05;***与模型组相比较,P<0.001;**与模型组相比较,P<0.01;*与模型组比较,P<0.05。
(2)本发明所得的药菌组合物含量指标如下:
水含量≦40-50%,总多糖含量≧4.36g/100mL,总酚含量≧5.00mg/mL,总黄酮含量≧4.50mg/mL。
综上可知,本发明产品能够显著降低高血脂症大鼠血清中TG、TC的含量,降低血清血脂水平,提高血清中HDL-C的水平。总的来说,以上结果说明本发明产品具有显著治疗高血脂症的效果,可以作为一种具有良好治疗高血脂症效果的药物。
显然,上述实施例仅仅是为清楚地说明所作的举例,并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引申出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (10)
1.一种治疗高血脂症的药菌组合物的制备方法,其特征在于,包括以下步骤:
S1、通过蒸馏浓缩方法制备醋膏,与茶粉混合,获得茶醋混合物;
S2、将嗜黏蛋白阿克曼氏菌(Akkermansia muciniphila)在35~38℃下厌氧发酵35~45h,得到活菌;
S3、将上述茶醋混合物加入活菌培养基中,在35~38℃下厌氧发酵15~35h,得到药菌混合物;
S4、对上述药菌混合物进行调配,灭菌后得到所述治疗高血脂症的药菌组合物。
2.根据权利要求1所述的制备方法,其特征在于:在步骤S1中,所述醋膏的制备方法为,将食醋于60℃~80℃加热蒸馏浓缩20~30h,收集浓缩醋液,向其中加入酵母抽提物,混匀后分层,取下层液得到醋膏。
3.根据权利要求2所述的制备方法,其特征在于:浓缩醋液与酵母抽提物的质量比为100-300:1-1.5。
4.根据权利要求1所述的制备方法,其特征在于:所述茶粉通过超微粉碎法将绿茶叶粉碎得到。
5.根据权利要求1所述的制备方法,其特征在于:茶醋混合物中,醋膏为茶粉质量的20~30%。
6.根据权利要求1所述的制备方法,其特征在于:在步骤S3中,所述嗜黏蛋白阿克曼氏菌(Akkermansia muciniphila)的添加量为4×108~4×1011个/100mL茶醋混合物。
7.根据权利要求1所述的制备方法,其特征在于:在步骤S4中,所述的调配为,向所述药菌混合物中加入水果果浆。
8.根据权利要求7所述的制备方法,其特征在于:所述水果选自苹果、火龙果、圣女果和猕猴桃中的至少两种。
9.权利要求1-8任一项所述的制备方法得到的药菌组合物。
10.权利要求9所述的药菌组合物在制备高血脂症预防或治疗药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311030575.3A CN116999519A (zh) | 2023-08-16 | 2023-08-16 | 一种治疗高血脂症的药菌组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311030575.3A CN116999519A (zh) | 2023-08-16 | 2023-08-16 | 一种治疗高血脂症的药菌组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116999519A true CN116999519A (zh) | 2023-11-07 |
Family
ID=88576111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311030575.3A Pending CN116999519A (zh) | 2023-08-16 | 2023-08-16 | 一种治疗高血脂症的药菌组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116999519A (zh) |
-
2023
- 2023-08-16 CN CN202311030575.3A patent/CN116999519A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104982928B (zh) | 一种红豆杉果保健酵素及其制备方法 | |
KR101595426B1 (ko) | 진세노사이드 성분이 증가된 가공인삼분말 또는 가공인삼추출물을 함유하는 암 관련 피로의 예방 및 치료용 조성물 | |
CN103494277A (zh) | 一种降脂减肥荷叶饮料及其制备方法 | |
CN109125525B (zh) | 防治心血管疾病的组合物及其制备方法和应用 | |
KR101614574B1 (ko) | 탱자 발효물에 의한 비만개선효과물질의 조성 | |
JP6626035B2 (ja) | 筋肉減少症の予防または治療用薬学組成物及び予防または改善用健康機能食品組成物 | |
CN113974043A (zh) | 一种益生元固体饮料及其制备方法 | |
CN110710660A (zh) | 含有苦瓜粉的降低血糖组合物及膳食补充剂 | |
KR101859166B1 (ko) | 인삼이 함유된 한약재 추출물을 유효성분으로 함유하는 숙취 해소용 조성물 | |
KR20160141027A (ko) | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
KR20180098888A (ko) | 땅콩새싹 추출물을 유효성분으로 포함하는 면역력 증강용 조성물 | |
CN116999519A (zh) | 一种治疗高血脂症的药菌组合物及其制备方法和应用 | |
CN113559150B (zh) | 一种蚕蛹-桑汁复合发酵制剂的制备方法及应用 | |
CN113143962B (zh) | 一种治疗高脂血症的药物组合物及其制备方法 | |
JP2013177330A (ja) | イモ焼酎粕又はその処理物を含む抗炎症剤 | |
CN111357902A (zh) | 一种降血脂功能性饮料及其制备方法 | |
KR101898891B1 (ko) | 진세노사이드 화합물 k를 이용한 세포독성 항암제 부작용 억제용 조성물 | |
CN111528459A (zh) | 以牡丹油为基料的清热降脂的营养食品及其制备方法 | |
KR20040097813A (ko) | 식욕억제, 체지방 감소 및 배변 활성화등 3가지 기능을 갖는 항비만 기능성 조성물 | |
KR102217834B1 (ko) | 케피어 유래 유산균의 사균체 및 포도씨 분말을 함유하는 비만의 예방 또는 치료용 조성물 | |
CN116617258A (zh) | 一种治疗溃疡性结肠炎药菌组合物的制备方法及应用 | |
KR101890853B1 (ko) | 프로타민 및 키토올리고당을 포함하는 비만의 예방 또는 치료용 조성물 | |
CN112957403A (zh) | 一种治疗酒精性肝损伤的药菌组合物及其制备方法与应用 | |
JP2022091992A (ja) | 筋肉減少症の予防または治療用薬学組成物及び予防または改善用健康機能食品組成物 | |
KR20170024700A (ko) | 마가목 열매 추출물을 유효성분으로 하는 비만, 당뇨 또는 비알코올성 지방간 질환 치료, 개선 또는 예방용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |